Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Kasenda

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 5, 2012
Prognosis after high-dose chemotherapy followed by autologous stem-cell transplantation as first-line treatment in primary CNS lymphoma--a long-term follow-up studyB Kasenda, E Schorb, K Fritsch, et al.
British Journal of Cancer|January 23, 2016
Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanomaS Diem, B Kasenda, L Spain, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 10, 2011
Immunochemotherapy with rituximab, methotrexate, procarbazine, and lomustine for primary CNS lymphoma (PCNSL) in the elderlyK Fritsch, B Kasenda, C Hader, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 3, 2015
Planning and reporting of quality-of-life outcomes in cancer trialsS Schandelmaier, K Conen, E von Elm, et al.
ESMO Open|January 8, 2022
Targeting immunoliposomes to EGFR-positive glioblastomaB Kasenda, D König, M Manni, et al.
ESMO Real World Data and Digital Oncology|April 3, 2026
Final results of the INFINITY precision oncology registry: non-standard targeted treatments in patients with advanced cancers in routine careL Sellmann, D Marschner, U M Martens, et al.
Leukemia|June 1, 2017
High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma: a prospective multicentre trial by the German Cooperative PCNSL study groupB Kasenda, G Ihorst, R Schroers, et al.
Bone Marrow Transplantation|April 25, 2017
High-dose thiotepa-based chemotherapy with autologous stem cell support in elderly patients with primary central nervous system lymphoma: a European retrospective studyE Schorb, C P Fox, K Fritsch, et al.
Immuno-Oncology Technology|January 13, 2025
Adoptive cell therapy with tumor-infiltrating lymphocytes in combination with nivolumab in patients with advanced melanomaD König, B Kasenda, M Sandholzer, et al.
Leukemia|November 16, 2016
High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study)K Fritsch, B Kasenda, E Schorb, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 5, 2012
Prognosis after high-dose chemotherapy followed by autologous stem-cell transplantation as first-line treatment in primary CNS lymphoma--a long-term follow-up studyB Kasenda, E Schorb, K Fritsch, et al.
British Journal of Cancer|January 23, 2016
Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanomaS Diem, B Kasenda, L Spain, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 10, 2011
Immunochemotherapy with rituximab, methotrexate, procarbazine, and lomustine for primary CNS lymphoma (PCNSL) in the elderlyK Fritsch, B Kasenda, C Hader, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 3, 2015
Planning and reporting of quality-of-life outcomes in cancer trialsS Schandelmaier, K Conen, E von Elm, et al.
ESMO Open|January 8, 2022
Targeting immunoliposomes to EGFR-positive glioblastomaB Kasenda, D König, M Manni, et al.
ESMO Real World Data and Digital Oncology|April 3, 2026
Final results of the INFINITY precision oncology registry: non-standard targeted treatments in patients with advanced cancers in routine careL Sellmann, D Marschner, U M Martens, et al.
Leukemia|June 1, 2017
High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma: a prospective multicentre trial by the German Cooperative PCNSL study groupB Kasenda, G Ihorst, R Schroers, et al.
Bone Marrow Transplantation|April 25, 2017
High-dose thiotepa-based chemotherapy with autologous stem cell support in elderly patients with primary central nervous system lymphoma: a European retrospective studyE Schorb, C P Fox, K Fritsch, et al.
Immuno-Oncology Technology|January 13, 2025
Adoptive cell therapy with tumor-infiltrating lymphocytes in combination with nivolumab in patients with advanced melanomaD König, B Kasenda, M Sandholzer, et al.
Leukemia|November 16, 2016
High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study)K Fritsch, B Kasenda, E Schorb, et al.
Pageof 2